About us
OBJECTIVE
OBJECTIVE
Our aim is to structure and facilitate research into Alzheimer’s disease and related disorders accross
Europe to improve our knowledge of the genetics of these diseases, to better understand the pathophysiological processes involved, and to enable the development and validation of biomakers.
COUNTRY
number : 17
Almost 100,000 biological samples including DNA, plasma or CSF
More than
80 participating laboratories and
clinical centres
5 European consortium partners
WHAT WE DO
WHAT WE DO
Initially dedicated to the collection and generation of large GWAS datasets, the EADB is expanding its scope to include sequencing data (whole exomes and genomes) and is investigating CSF and plasma biomarkers/proteomics (related to genetics).
Genetics of Alzheimer’s disease
Genetics of conversion from MCI cases to AD
and related dementia
Genetics of vascular cognitive impairments and dementia
Genetics of other neurodegenerative diseases
Validation and development of biomarkers
Genetics of AD biomarkers
CONSTITUENT CONSORTIUMS
The EADB and its partners welcome all types of collaborations on genetics and biomarkers. Please do not hesitate to contact us
CONSTITUENT CONSORTIUMS
GR@ace
Genomic Research
Applied to Alzheimer’s
Disease
GERAD
Genetic and Environmental
Risk in Alzheimer’s Disease
Consortium.
EADI
European Alzheimer
Disease Initiative
DEMGENE
The Norwegian
DemGene Network
DEGESCO
Dementia Genetic
Spanish Consortium
